Literature DB >> 15128356

Predictors of alternative and complementary medicine use in inflammatory bowel disease: do measures of conventional health care utilization relate to use?

Twila Burgmann1, Patricia Rawsthorne, Charles N Bernstein.   

Abstract

OBJECTIVE: Alternative and complementary therapies (ACM) have gained increasing attention in the past few years. It was our purpose to determine whether increased ACM use is associated with increased use of conventional health care resources. Additionally, demographics of use, subjective benefit, and cost were analyzed.
METHODS: We enrolled 150 inflammatory bowel disease (IBD) patients from a tertiary care center and performed a phone survey of their ACM use in the past year. A population-based administrative database was accessed to extract data regarding use of conventional medicine (hospitalizations, doctor visits, and GI specific doctor visits). Patients were divided into three groups: (i) no ACM (n = 60) (ii) users of exercise, diet, and prayer (EDP) exclusively (n = 47) (iii) other ACM use (n = 43) which included those who may have used EDP as well as any of acupuncture, chiropractic, homeopathy, naturopathy, herbology, massage, relaxation, reflexology, hypnotherapy, aromatherapy, meditation, or support group.
RESULTS: ACM was used by 60% (EDP 31%, other ACM 29%). There were no significant differences in use between the three groups by disease diagnosis, education level, employment status, use of IBD medications, number of hospitalizations, doctor visits, or GI specific doctor visits. The EDP group was more likely to be married (p = 0.006) and female (p = 0.04) compared to no ACM. The EDP group tended to be older than the no ACM (p = 0.001) and other ACM (p = 0.01). The other ACM had shorter disease duration than EDP (p = 0.04) and no ACM (p = 0.04). The most commonly used therapies were diet (45%), herbal (17%), exercise (15%), prayer (11%), and relaxation (10%). ACM was sought for pain/cramps (64%), diarrhea (60%), and gas/bloating (21%). Seventy-three percent of EDP interventions incurred no cost compared to 33% with other ACM (p < 0.0001). The median annual amount spent on other ACM was $56 (range $0-$4800). Subjectively, patients felt helped by trials of EDP 95% of the time whereas other ACM helped 67% of the time (p < 0.0001).
CONCLUSIONS: ACM use could not be predicted by either greater or less hospitalizations, conventional doctor visits, or GI specific visits. ACM was sought mostly to palliate pain or diarrhea. Those using EDP are more likely to be older married women. Subjectively other ACM is of less benefit (67%) than EDP (95%). If doctor visits or hospitalizations represent degree of increased disease activity then this too is not predictive of using ACM.

Entities:  

Mesh:

Year:  2004        PMID: 15128356     DOI: 10.1111/j.1572-0241.2004.30033.x

Source DB:  PubMed          Journal:  Am J Gastroenterol        ISSN: 0002-9270            Impact factor:   10.864


  17 in total

1.  European evidence based consensus on the diagnosis and management of Crohn's disease: special situations.

Authors:  R Caprilli; M A Gassull; J C Escher; G Moser; P Munkholm; A Forbes; D W Hommes; H Lochs; E Angelucci; A Cocco; B Vucelic; H Hildebrand; S Kolacek; L Riis; M Lukas; R de Franchis; M Hamilton; G Jantschek; P Michetti; C O'Morain; M M Anwar; J L Freitas; I A Mouzas; F Baert; R Mitchell; C J Hawkey
Journal:  Gut       Date:  2006-03       Impact factor: 23.059

2.  Optimizing management of Crohn's disease within a project management framework: results of a pilot study.

Authors:  Laurie Keefer; Bethany Doerfler; Caroline Artz
Journal:  Inflamm Bowel Dis       Date:  2011-02-23       Impact factor: 5.325

3.  The potential role of a self-management intervention for ulcerative colitis: a brief report from the ulcerative colitis hypnotherapy trial.

Authors:  Laurie Keefer; Jennifer L Kiebles; Monika A Kwiatek; Olafur Palsson; Tiffany H Taft; Zoran Martinovich; Terrence A Barrett
Journal:  Biol Res Nurs       Date:  2011-02-28       Impact factor: 2.522

Review 4.  Non-pharmacological therapies for inflammatory bowel disease: Recommendations for self-care and physician guidance.

Authors:  Whitney Duff; Natasha Haskey; Gillian Potter; Jane Alcorn; Paulette Hunter; Sharyle Fowler
Journal:  World J Gastroenterol       Date:  2018-07-28       Impact factor: 5.742

Review 5.  Use of Evidence-Based Herbal Medicines for Patients with Functional Gastrointestinal Disorders: A Conceptional Framework for Risk-Benefit Assessment and Regulatory Approaches.

Authors:  Gerald Holtmann; Dietmar Schrenk; Ahmed Madisch; Hans D Allescher; Gudrun Ulrich-Merzenich; Fermin Mearin; Dominique Larrey; Peter Malfertheiner
Journal:  Dig Dis       Date:  2019-11-26       Impact factor: 2.404

6.  Electroacupuncture reduces rectal distension-induced blood pressure changes in conscious dogs.

Authors:  Masahiro Iwa; Carmen Strickland; Yukiomi Nakade; Theodore N Pappas; Toku Takahashi
Journal:  Dig Dis Sci       Date:  2005-07       Impact factor: 3.199

7.  What effect does chiropractic treatment have on gastrointestinal (GI) disorders: a narrative review of the literature.

Authors:  Katherine Angus; Sepideh Asgharifar; Brian Gleberzon
Journal:  J Can Chiropr Assoc       Date:  2015-06

8.  Electroacupuncture elicits dual effects: stimulation of delayed gastric emptying and inhibition of accelerated colonic transit induced by restraint stress in rats.

Authors:  Masahiro Iwa; Yukiomi Nakade; Theodore N Pappas; Toku Takahashi
Journal:  Dig Dis Sci       Date:  2006-07-26       Impact factor: 3.199

9.  Electroacupuncture at acupoint ST-36 promotes contractility of distal colon via a cholinergic pathway in conscious rats.

Authors:  Dan Luo; Shi Liu; Xiaoping Xie; Xiaohua Hou
Journal:  Dig Dis Sci       Date:  2007-08-31       Impact factor: 3.199

10.  A survey of perceptions and practices of complementary alternative medicine among Canadian gastroenterologists.

Authors:  Zane Gallinger; Brian Bressler; Shane M Devlin; Sophie Plamondon; Geoffrey C Nguyen
Journal:  Can J Gastroenterol Hepatol       Date:  2013-11-08
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.